REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the 35th Annual Piper Sandler Healthcare Conference, being held November 28-30, 2023, in New York, New York.
Management will participate in a fireside chat on Tuesday, November 28, 2023, at 9:30 am ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, https://ir.codexis.com. A replay will be archived for 90 days following the event.
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Lauren Musto
(781) 572-1147
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.34 |
Daily Change: | 0.09 4.00 |
Daily Volume: | 734,724 |
Market Cap: | US$190.430M |
May 14, 2025 May 07, 2025 April 01, 2025 February 27, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load